UCLA spinoff ImaginAb and Duke-NUS Graduate Medical School Singapore will team up to develop in vivo molecular imaging agents focused on cancer, immunology and disease areas unique to Asia.
Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.
New York's Provista Diagnostics expanded a licensing deal for biomarker and autoantibody technology developed at Arizona State University--concepts first spotted at Harvard Medical School and the Dana-Farber Cancer Institute.
Quest Diagnostics and Memorial Sloan-Kettering Cancer Center are teaming up on a project designed to eventually improve diagnosis and treatment options for various cancers. Long-range, they have set their sights on developing a broad gene-sequencing diagnostic test.
Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug.
Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.
Cambridge, U.K.-based Lab21, which focuses on personalized medicine and clinical diagnostics, plans to become a subsidiary of Paris-based Novacyt, which makes cytology diagnostic tests and tools for various cancers.
Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.
Are you healthy? Do you have pancreatic cancer, pancreatitis or pancreatic cysts? In early testing, Texas researchers successfully used four blood biomarkers that aided in early-stage diagnosis to help tell the difference.
Evidence is mounting that circulating tumor cells in the bloodstream, also known as CTCs, are a viable cancer biomarker tool. A team in Germany produced new evidence that their presence, or absence, may be an effective way to measure the survival chance of patients with early breast cancer.